Jo Chien, MD
Professor
Medicine
School of Medicine
Dr. Chien specializes in the management and treatment of patients with breast cancer. She is Professor of Medicine at UCSF and the Helen Diller Family Comprehensive Cancer Center. Dr. Chien received her undergraduate degree from Stanford University and medical degree from Harvard Medical School.
Show full bio (260 words) Hide full bio
She subsequently completed her residency in Internal Medicine at Massachusetts General Hospital, and her fellowship in Hematology/Oncology at UCSF. She joined the UCSF faculty after completing her fellowship and serves as the Medical Director of Breast Medical Oncology at UCSF. Dr. Chien’s main research interest is in the translational and clinical development of novel treatment strategies for early stage and metastatic breast cancer. She serves as the Principal Investigator of numerous investigator-initiated as well as industry-sponsored trials targeting all breast cancer subtypes including estrogen receptor-positive (ER+), HER2-positve, and triple negative breast cancer. She is the UCSF site PI of the multi-center I-SPY2 trial. She leads the ISPY2 Endocrine Optimization Protocol (EOP) sub-study which is taking a novel and comprehensive approach to identifying innovative and better tolerated strategies for the treatment of ER+ early stage breast cancer. Through this study she is investigating new technologies and methods for evaluating response to endocrine therapy including molecular, pathologic, and radiologic endpoints. Through these efforts, Dr. Chien aims to identify which patients need more aggressive treatment (and to provide targeted treatment options for these patients), and which patients can do well with less intervention. Dr. Chien is also interested in the impact of a breast cancer diagnosis and treatment on young women. She started a large registry of young women with breast cancer which serves as a rich resource for research, and facilitates clinical support for young women. Dr. Chien’s work has been funded by the NIH, NCI, DOD, ASCO, American Cancer Society, California Breast Cancer Research Program, and philanthropic support.
Education & Training
Show all (4) Hide
- Heme/Onc Fellowship, Chief Fellow UCSF 2009
- M.D. School of Medicine Harvard University
- Internal Medicine Residency Massachusetts General Hospital
- B.S. Biological Sciences with Honors Stanford University
Websites
Show all (1) Hide
- Profile at UCSF Cancer Center (cancer.ucsf.edu)
Publications (64)
Top publication keywords:
Antineoplastic Agents, HormonalHeterocyclic Compounds, 3-RingBreast NeoplasmsInfertility, FemaleNeoadjuvant TherapyOvulation InductionAntineoplastic Combined Chemotherapy ProtocolsPaclitaxelFertility PreservationTamoxifenReceptor, ErbB-2Neoplasms, Hormone-DependentQuinolinesQuinazolinesTrastuzumab
-
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
Breast cancer research and treatment 2023 Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS -
Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Clinical breast cancer 2023 Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, Chien AJ -
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
Breast cancer research and treatment 2023 Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Symmans WF, Schwartz CJ, Chien AJ, Mukhtar RA -
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
JAMA oncology 2023 Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, … -
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
Breast cancer research and treatment 2023 Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, …
Show all (59 more) Hide
-
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Breast (Edinburgh, Scotland) 2022 Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N… -
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
NPJ breast cancer 2022 Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS,… -
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study.
Breast cancer research and treatment 2022 Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, Melisko ME, Rugo HS, Behr S, Chien AJ -
ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
Annals of surgical oncology 2022 Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA -
The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
Annals of surgical oncology 2022 Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA -
Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting.
Cell reports. Medicine 2022 Chien AJ, Kyalwazi B, Esserman LJ -
Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study.
JMIR cancer 2022 Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M -
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
NPJ breast cancer 2021 Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA -
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Nature communications 2021 Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis … -
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
JAMA oncology 2021 Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, … -
Emerging immunotherapeutic strategies for the treatment of breast cancer.
Breast cancer research and treatment 2021 Huppert LA, Mariotti V, Chien AJ, Soliman HH -
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
NPJ breast cancer 2021 Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA -
Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
Journal of assisted reproduction and genetics 2021 Letourneau J, Juarez-Hernandez F, Wald K, Ribeiro S, Wang A, McCulloch CE, Mok-Lin E, Dolezal M, Chien AJ, Cedars MI, Rosen M -
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Cancer cell 2021 Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, … -
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
NPJ breast cancer 2021 Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L -
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
Annals of oncology : official journal of the European Society for Medical Oncology 2021 Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R,… -
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast cancer research and treatment 2021 Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A,… -
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
Annals of oncology : official journal of the European Society for Medical Oncology 2020 Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H… -
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
Journal of the National Comprehensive Cancer Network : JNCCN 2020 Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, Hirst GL, Flavell RR, Chien AJ, Yee D, Isaacs CJ, Forero-Torres A, Esserman LJ, Melisko ME -
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
NPJ breast cancer 2020 Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer… -
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
JAMA oncology 2020 I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-… -
Multidisciplinary Management of Cancer During Pregnancy.
JCO oncology practice 2020 Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, Van Loon K -
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN -
Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
Cancers 2020 Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM -
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, … -
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Annals of oncology : official journal of the European Society for Medical Oncology 2020 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz… -
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
JAMA oncology 2020 Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, … -
Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
Cancer 2019 Letourneau JM, Wald K, Sinha N, Juarez-Hernandez F, Harris E, Cedars MI, McCulloch CE, Dolezal M, Chien AJ, Rosen MP -
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
NPJ breast cancer 2019 Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ -
Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
Clinical breast cancer 2019 Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME -
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
NPJ breast cancer 2019 Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM -
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, … -
Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
Human reproduction (Oxford, England) 2017 Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, Mok-Lin E, Chien AJ, Rosen M -
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN -
Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Chien AJ, Rugo HS -
Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Breast cancer research and treatment 2017 Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP -
Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Breast cancer research and treatment 2017 Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP -
Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
JAMA oncology 2017 Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS -
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
Clinical breast cancer 2016 Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM -
Adaptive Randomization of Neratinib in Early Breast Cancer.
The New England journal of medicine 2016 Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, … -
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
The New England journal of medicine 2016 Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS,… -
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Breast cancer research and treatment 2016 Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN -
HER2-positive breast cancer: is more treatment better?
The Lancet. Oncology 2016 Rugo HS, Chien AJ -
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
Breast cancer research and treatment 2015 Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP -
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, … -
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM -
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.
The International journal of biological markers 2013 Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L -
Developing safety criteria for introducing new agents into neoadjuvant trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013 DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P… -
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B,… -
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.
Breast cancer research and treatment 2012 Chien AJ, Rugo HS -
The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.
Breast cancer research and treatment 2012 Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M -
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
Breast cancer research and treatment 2011 Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN -
Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer.
Cancer 2011 Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP -
Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer.
Cancer 2011 Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP -
The cardiac safety of trastuzumab in the treatment of breast cancer.
Expert opinion on drug safety 2010 Chien AJ, Rugo HS -
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM -
Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Cancer treatment and research 2009 Jo Chien A, Rugo HS -
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
Seminars in oncology 2008 Chien AJ, Moasser MM -
Aromatase inhibitors and bone health in women with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Chien AJ, Goss PE